

October 26, 2007

Starpharma Pty Ltd  
Baker Building  
75 Commercial Road  
Melbourne VIC 3004  
AUSTRALIA  
Attn: Jeremy Paull, Phd, via electronic communication

Dear Dr. Paull,

We write to you in response to the announcement made on October 16, 2007 (<http://www.starpharma.com/data/071016%20Durex%20codevelopment%20agreement%20for%20VivaGel%20coated%20condoms.pdf>) about the agreement between Starpharma and SSL International to pursue VivaGel as a potential condom-coating product.

This announcement has elicited strong interest among microbicides advocates and researchers, who have asked us to provide them with more information about your plans for VivaGel. We are hoping that we can work with you as a conduit for this dialogue.

Specifically, any information you can share with us on the following topics would be greatly appreciated:

- VivaGel has already been tested for vaginal safety in one trial and is currently undergoing testing in two other vaginal safety trials. What other trials are being considered? Are you planning to conduct any safety trials looking at rectal safety specifically?
- What endpoints are you hoping to establish for VivaGel before considering its use for condom coating: HIV? HSV-2? Contraception?
- What research is planned to assess the endpoints?
- Have you established any timelines for this research?

As you can well imagine, some of these questions have emerged as a result of the field's experience with Nonoxynol-9. We are aware that SSL International is the only major condom manufacturer to date to have stopped producing N-9 condoms, and we remain hopeful that this leadership will translate into careful consideration for the establishment of rigorous vaginal and rectal safety and efficacy profiles for any product used for condom coating.

We thank you in advance for your consideration, and remain available to discuss any questions or concerns you may have.

The Global Campaign for Microbicides (GCM) is a broad-based, international effort to build support among policymakers, opinion leaders, and the general public for increased investment into microbicides and other user-controlled prevention methods.

The International Rectal Microbicides Working Group (IRMWG) is a network of advocates, researchers and policy-makers across five continents dedicated to accelerated research, development and access to safe and effective rectal microbicides.

Sincerely,

Lori Heise

Handwritten signature of Lori Heise in cursive script.

Director  
GCM

Jim Pickett

Handwritten signature of Jim Pickett in cursive script.

Chair  
IRMWG